HIV-infected cohort clinical information
| Patient characteristics . | ECs (IQR) . | CPs (IQR) . | HAART-suppressed (IQR) . |
|---|---|---|---|
| Number of subjects | 20 | 18 | 19 |
| Median plasma HIV RNA, copies/mL | undetectable | 28 908 (15 904-49 686) | undetectable |
| Median CD4+ T-cell count, cells/mm3 | 772 (664-1133) | 622 (461 734) | 675 (493-868) |
| Median infection duration, y | 17 (11-20) | 6 (3-16) | 14 (10-20) |
| Median duration of HAART treatment prior to specimen sample, y | N/A | N/A | 5 (4-7) |
| Patient characteristics . | ECs (IQR) . | CPs (IQR) . | HAART-suppressed (IQR) . |
|---|---|---|---|
| Number of subjects | 20 | 18 | 19 |
| Median plasma HIV RNA, copies/mL | undetectable | 28 908 (15 904-49 686) | undetectable |
| Median CD4+ T-cell count, cells/mm3 | 772 (664-1133) | 622 (461 734) | 675 (493-868) |
| Median infection duration, y | 17 (11-20) | 6 (3-16) | 14 (10-20) |
| Median duration of HAART treatment prior to specimen sample, y | N/A | N/A | 5 (4-7) |
IQR indicates interquartile range; ECs, elite controllers; CPs, chronically infected progressors; and HAART, highly active antiretroviral therapy.